The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised




About Salus Therapeutics

Salus Therapeutics develops oligonucleotide pharmaceuticals intended to block or regulate the production of disease-related proteins at the genetic level.

Salus Therapeutics Headquarter Location

Salt Lake City, Utah,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Salus Therapeutics News

MediConnect Global Adds Dinesh Patel to Board

Aug 9, 2011

Tweet Salt Lake City-based MediConnect Global, the developer of medical health records retrieval software, said today that it has tapped Dinesh Patel for its board of directors. Patel is a well known Utah entrepreneur and investor, and was a co-founder of vSpring Capital, co-founder and CEO of Theratech, and also founded Ashni Naturaceuticals and Salus Therapeutics. Other board members at MediConnect include James Lee Sorenson, Alan Hall, Charles Johnson of Leavitt Partners, and Intermountain Healthcare's Scott Parker.

  • When was Salus Therapeutics founded?

    Salus Therapeutics was founded in 1999.

  • Where is Salus Therapeutics's headquarters?

    Salus Therapeutics's headquarters is located at Salt Lake City.

  • What is Salus Therapeutics's latest funding round?

    Salus Therapeutics's latest funding round is Acquired.

  • How much did Salus Therapeutics raise?

    Salus Therapeutics raised a total of $4.25M.

  • Who are the investors of Salus Therapeutics?

    Investors of Salus Therapeutics include Genta, WS Investments, vSpring Capital and Pelion Venture Partners.

  • Who are Salus Therapeutics's competitors?

    Competitors of Salus Therapeutics include Cevec Pharmaceuticals, Acura Pharmaceuticals, Esperance Pharmaceuticals, Angstrom Pharmaceuticals, Oxyrane and 12 more.

You May Also Like


Oxyrane is a biopharmaceutical company dedicated to the development of biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases.

Wrightwood Technologies

The company are a technology development and licensing firm with a strong focus on robotics and machine intelligence applications and their integration into industries such as pharmaceuticals and health care. The company take great pride in the company's diverse and knowledgeable staff, who make such ventures possible. Wrightwood Technologies Inc. aims to provide both the public and private sectors with technologies and services that improve efficiency, increase production, reduce costs, eliminate waste, and improve societies' over-all quality of life.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..


Neuromark is aiming to develop genetic answers for the new era in neuropsychiatry.

Message Pharmaceuticals

Message Pharmaceuticals, Inc. is leveraging its platform technology in developing new classes of drugs that mimic RNA binding proteins to treat all major disease categories.

Frio Pharmaceuticals

Frio Pharmaceuticals is dedicated to oral-systemic health and was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform technology has evolved into a pipeline of pharmaceuticals to treat oral diseases and interrupt the disease process. Its goal is to commercialize a broad-spectrum antimicrobial platform technology with products being: (1) a pharmaceutical to treat thrush (oral candidiasis) in cancer patients with thrush and (2) a pharmaceutical to treat gingivitis (oral inflammation).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.